Synthesis of new vasotocin analogues: Effects on renal water and ion excretion in rats

Journal of Peptide Science

Volumn 19, Issue 5, 2013, Pages 268-276

  Kutina, Anna V ^a   Marina, Anna S ^a   Eliseev, Ivan I ^b   Titov, Mikhail I ^b   Natochin, Yuri V ^a  

^a SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

^b ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

Author keywords

Analogues; Antidiuresis; Kaliuresis; Kidney; Natriuresis; Neurohypophysial nonapeptides; Vasopressin; Vasotocin

Indexed keywords

ANTIDIURETIC AGENT; ARGININE; ARGIPRESSIN DERIVATIVE; GLYCINE; LEUCINE; MERCAPTOPROPIONIC ACID; OXYTOCIN DERIVATIVE; POTASSIUM; PROPIONIC ACID DERIVATIVE; SODIUM; THREONINE; UNCLASSIFIED DRUG; VASOPRESSIN DERIVATIVE; VASOTOCIN DERIVATIVE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIDIURESIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DEAMINATION; DIURESIS; DIURETIC ACTIVITY; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; IN VIVO STUDY; KALIURESIS; NATRIURESIS; NONHUMAN; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; POTASSIUM TRANSPORT; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RAT; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SODIUM URINE LEVEL; WATER TRANSPORT;

ANIMALS; IONS; KIDNEY; MALE; PERMEABILITY; POTASSIUM; RATS; RATS, WISTAR; SODIUM; STRUCTURE-ACTIVITY RELATIONSHIP; VASOTOCIN; WATER;

ANURA; MAMMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84876416747     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2495     Document Type: Article

References (51)

1. du Vigneaud V, Cash DT, Karsoyannis PG. A synthetic preparation possessing biological properties associated with arginine-vasopressin. J. Am. Chem. Soc. 1954; 79: 4751-4752.
2. Dudley DJ. Complications of labor, In Danforth's Obstetrics and Gynecology. 10th ed. (Eds: Gibbs RS, Karlan BY, Haney AF, Nygaard I). LWW: Philadelphia, 2008; 431-451.
3. Vavra I, Machova A, Holecek V, Cort JH, Zaoral M, Sorm F. Effect of a synthetic analogue of vasopressin in animals and in patients with diabetes insipidus. Lancet 1968; 291: 948-952.
4. Natochin YV, Kuznetsova AA. Nocturnal enuresis: correction of renal function by desmopressin and diclofenac. Pediatr. Nephrol. 2000; 14: 42-47.
5. Van Kerrebroeck PEV. Nocturia and antidiuretic pharmacotherapy, In Nocturia. Causes, Consequences and Clinical approaches (Eds: Weiss JP, Blaivas JG, Van Kerrebroeck PEV, Wein AJ). Springer: Berlin, Heidelberg, New York, London, 2012; 135-146.
6. Saner FH, Canbay A, Gerken G, Broelsch CE. Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome. Expert Rev. Gastroenterol. Hepatol. 2007; 1: 207-217.
7. nd ed. (Eds: Michelson AD). Academic Press: San Diego, CA, 2005; 1237-1250.
8. nd ed. Springer: Berlin, Heidelberg, New York, 2002; V. 1.
9. Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J. Endocrinol. 1998; 156: 223-229.
10. Jard S, Elands J, Schmidt A, Barberis C. Vasopressin and oxytocin receptors: an overview, In Progress in Endocrinology (Eds: Imura H, Shizume K). Elsevier: Amsterdam, 1988; 1183-1188.
11. Vávra I, Machová A, Krejcí I. Antidiuretic action of 1-deamino-(8-d-arginine)-vasopressin in unanesthetized rats. J. Pharmacol. Exp. Ther. 1974; 188: 241-247.
12. Balment RJ, Brimble MJ, Forsling ML, Musabayane CT. Natriuretic response of the rat to plasma concentrations of arginine vasopressin within the physiological range. J. Physiol. 1984; 352: 517-526.
13. Hrbas P, Skopková J, Zicha J, Barth T, Lebl M, Jost K. Nacartocin - analogue of oxytocin with enhanced natriuretic properties: natriuretic and hemodynamic characteristics. Endocrinol. Exp. 1984; 18: 117-124.
14. Skopková J, Barth T, Hrbas P, Jost K, Lebl M Natriuretic properties of [2-p-ethylphenylalanine] deamino-6-carba-oxytocin (Nacartocin) in cats. Exp. Clin. Endocrinol. 1984; 84: 235-238.
15. Machová A Antidiuretic activity of terlipressin (triglycyl-lysine vasopressin) - role of pressure natriuresis. Physiol. Res. 1992; 41: 121-127.
16. Kutina AV, Eliseev II, Titov MI, Natochin YV. Replacement of l-arginine(8) by d-arginine(8) cancels the natriuretic effect of arginine vasotocin analogs in rats. Dokl. Biol. Sci. 2008; 422: 298-300.
17. Kutina AV, Eliseev II, Titov MI, Bogolepova AE, Shakhmatova EI, Natochin IuV. Selective effect of vasotocin analogues with amino acid substitutions in 4, 7, 8 positions on the water and cations excretion by the rat kidney. Ross. Fiziol. Zh. Im. I M Sechenova 2009; 95: 204-214.
18. Kutina AV, Marina AS, Zaitseva KV, Eliseev II, Titov MI, Natochin IuV. Influence of new neurohypophysial hormone analogs on sodium and water reabsorption in rat kidney. Eksp. Klin. Farmakol. 2010; 73: 21-24.
19. Grzonka Z, Kasprzykowski F, Kojro E, Darlak K, Melin P, Fahrenholz F, Crause P, Boer R. Arginine-vasopressin analogues with high antidiuretic/vasopressor selectivity. Synthesis, biological activity, and receptor binding affinity of arginine-vasopressin analogues with substitutions in positions 1, 2, 4, 7, and 8. J. Med. Chem. 1986; 29: 96-99.
20. Larsson LE, Lindeberg EG, Melin P. Solid phase synthesis and some hormonal activities of 8-l-homoarginine-vasotocin and 1-deamino-8-l-homoarginine-vasotocin. Int. J. Pept. Protein Res. 1977; 9: 182-186.
21. Manning M, Coy EJ, Acosta M, Sawyer WH. Solid-phase synthesis and some pharmacological properties of deamino-4-threonine analogs of the vasopressins and vasotocin and (deamino)arginine-vasotocin. J. Med. Chem. 1973; 16: 836-839.
22. Dutertre S, Croker D, Daly NL, Andersson A, Muttenthaler M, Lumsden NG, Craik DJ, Alewood PF, Guillon G, Lewis RJ. Conopressin-T from Conus tulipa reveals an antagonist switch in vasopressin-like peptides. J. Biol. Chem. 2008; 283: 7100-7108.
23. Kruszyński M, Manning M, Wo NC, Sawyer WH. Invertebrate neuropeptides resembling vasotocin and some analogues: synthesis and pharmacological properties. Experientia 1990; 46: 771-773.
24. Lebl M, Sugg EE, van Binst G, Vander Elst P, Tourwé D, Slaninová J, Hruby VJ. Analogs of oxytocin containing a modified peptide bond. Int. J. Pept. Protein Res. 1987; 30: 318-322.
25. Rekowski P, Lammek B, Melin P, Ragnarsson U, Kupryszewski G. Synthesis, antidiuretic and pressor activities of [arginine4]arginine-vasopressin and two related analogues. Acta Chem. Scand. B 1985; 39: 453-457.
26. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970; 34: 595-598.
27. Vojkovsky T. Detection of secondary amines on solid phase. Pept. Res. 1995; 8: 236-237.
28. Recommended Standard Procedure. Formation of disulfide bridges from bis-Acm peptides. The Bachem Practice of SPPS. Tips and Tricks from the Experts at Bachem. (Eds: Mergler M, Durieux JP). Bachem AG: Bubendorf, 2005; 35-36.
29. Vemuri S. Comparison of assays for determination of peptide content for lyophilized thymalfasin. J. Pept. Res. 2005; 65: 433-439.
30. Cheesman DW, Schlegel R Effects of [1-(3-mercaptopropanoic acid)]-vasopressin and -vasotocin on the pro-oestrous progesterone surge and ovulation in immature female rats. J. Endocrinol. 1983; 97: 389-394.
31. Cheesman DW, Schlegel R, Sagasay AM, Forsham PH. Anovulatory effect of synthetic analogs of arginine vasotocin in the rat. Endocrinology 1983; 112: 269-276.
32. Karavashkina TA, Kutina AV, Shakhmatova EI, Natochin YuV. Mechanism of 1-deamino-arginine vasotocin induced natriuresis in rats. Gen. Comp. Endocrinol. 2011; 170: 460-467.
33. 2 receptor. Biol. Bull. 2011; 38: 615-621.
34. Smith HW. Principles of Renal Physiology. Oxford University Press: New York, 1956; 237.
35. Brod J. The Kidney. Butterworth: London, 1973; 133.
36. Stricker EM, Hoffmann ML. Inhibition of vasopressin secretion when dehydrated rats drink water. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005; 289: R1238-R1243.
37. Kutina AV, Marina AS, Titov MI, Natochin YV. Kaliuretic nonapeptide. Dokl. Biol. Sci. 2012; 444: 147-149.
38. Cort JH, Schück O, Stríbrná J, Skopková J, Jost K, Mulder JL. Role of the disulfide bridge and the C-terminal tripeptide in the antidiuretic action of vasopressin in man and the rat. Kidney Int. 1975; 8: 292-302.
39. Gazis D, Sawyer WH. Elimination of infused arginine-vasopressin and its long-acting deaminated analogue in rats. J. Endocrinol. 1978; 78: 179-186.
40. Walter R Partial purification and characterization of post-proline cleaving enzyme: enzymatic inactivation of neurohypophysial hormones by kidney preparations of various species. Biochim. Biophys. Acta 1976; 422: 138-158.
41. Chini B, Mouillac B, Ala Y, Balestre MN, Trumpp-Kallmeyer S, Hoflack J, Elands J, Hibert M, Manning M, Jard S, et al. Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. EMBO J. 1995; 14: 2176-2182.
42. Mouillac B, Chini B, Balestre MN, Elands J, Trumpp-Kallmeyer S, Hoflack J, Hibert M, Jard S, Barberis C. The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J. Biol. Chem. 1995; 270: 25771-25777.
43. Natochin YV, Buravkova LB, Shakhmatova EI, Larina IM, Kanashkina TA, Krotov VP, Az'muko AA, Ovchinnikov MV, Grigoriev AI. The effects of synthesized analogs of vasotocin on water and ion excretion by the rat and monkey kidneys. Dokl. Biol. Sci. 2006; 406: 11-13.
44. van Kesteren RE, Tensen CP, Smit AB, van Minnen J, Kolakowski LF, Meyerhof W, Richter D, van Heerikhuizen H, Vreugdenhil E, Geraerts WP. Co-evolution of ligand-receptor pairs in the vasopressin/oxytocin superfamily of bioactive peptides. J. Biol. Chem. 1996; 271: 3619-3626.
45. Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M, Guillon G. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J. Neuroendocrinol. 2012; 24: 609-628.
46. Vasopressin (Eds: Gross P, Richter D, Robertson GL). John Libbey Eurotext, Paris, 1993.
47. Wisniewski K, Galyean R, Taki H, Alagarsamy S, Croston G, Laporte R, Schteingart CD, Rivière PJ Synthesis and in vitro pharmacological profile of potent and selective peptidic V1a receptor agonists. Adv. Exp. Med. Biol. 2009; 611: 507-508.
48. Aronson JK. Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier Science: Amsterdam, 2009, 520-525.
49. Crofton JT, Ratliff DL, Brooks DP, Share L. The metabolic clearance rate of and pressor responses to vasopressin in male and female rats. Endocrinology 1986; 118: 1777-1781.
50. László FA, Varga C, Papp A, Pávó I, Fahrenholz F. Difference between male and female rats in vasopressor response to arginine vasopressin. Acta Physiol. Hung. 1993; 81: 137-145.
51. Wang YX, Crofton JT, Share L. Sex differences in the cardiovascular and renal actions of vasopressin in conscious rats. Am. J. Physiol. 1997; 272: R370-R376.